(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged advanced manufacturing, bioengineering jobs, cancer treatment manufacturing, Dallas Fort Worth biotech, Denton Texas, Greg Abbott, Novartis, Novartis Expands Radioligand Therapy Network with New Manufacturing Site in Denton Texas, Novartis Strengthens US Radioligand Therapy Production with Planned Texas Manufacturing Investment, nuclear medicine, oncology pipeline, pharmaceutical manufacturing, radioligand therapy RLT, radiopharmaceuticals, targeted radiation therapy, US investment program, Vas Narasimhan
(IN BRIEF) GSK announced that its B7-H3-targeted antibody-drug conjugate GSK5764227 (GSK’227) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer (SCLC). The designation is supported … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, cancer research, EMA, EMA Grants Orphan Drug Designation to GSK’s B7-H3 Antibody-Drug Conjugate for Pulmonary Neuroendocrine Carcinoma, FDA, GSK, GSK Strengthens Oncology Pipeline With EMA Orphan Drug Status for GSK’227 in Small-Cell Lung Cancer, GSK5764227, GSK’227, immuno-oncology, lung cancer, NEC, ODD, oncology, oncology pipeline, orphan drug designation, PRIME designation, pulmonary neuroendocrine carcinoma, relapsed or refractory, SCLC, Small cell lung cancer, solid tumours, targeted therapy
(IN BRIEF) BioNTech reported its second-quarter 2023 financial results and corporate update, highlighting significant pipeline advancements in oncology with the initiation of BNT316/ONC-392 Phase 3 pivotal trial and positive data updates across multiple technology platforms. The company also prepares for … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Management, News, Pharma & Biotech, Science
Tagged BioNTech, Financial, Jens Holstein, Omicron-Adapted COVID-19 Vaccine, oncology pipeline, partnership, Pfizer, Prof. Ugur Sahin
London, UK, 03-6-2014 — /EuropaWire/ — AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 June 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?